Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 25:9:826720.
doi: 10.3389/fsurg.2022.826720. eCollection 2022.

Clinicopathological Characteristics of Plurihormonal Pituitary Adenoma

Ruoyu Shi  1 , Xueyan Wan  1 , Zisheng Yan  1 , Zhoubin Tan  1 , Xiaojin Liu  1 , Ting Lei  1
Affiliations

Clinicopathological Characteristics of Plurihormonal Pituitary Adenoma

Ruoyu Shi et al. Front Surg. .

Abstract

Background: As the pathogenesis of plurihormonal pituitary adenoma (PPA) is unclear and the diagnostic criteria are inconsistent, clinicians still find it challenging to diagnose. To analyze the relationship between clinical and pathological characteristics in PPA.

Methods: The clinical data of patients with 70 PPAs admitted during 2008-2010 and 2019-2020 were collected and analyzed. In particular, hormone examination using cell culture supernatant was performed to confirm PPA cases from 2019 to 2020.

Results: PPA accounted for 13% of all pituitary cases recorded in the same period. There were 30 men and 40 women. Fifty-three percent of patients had one endocrine manifestation, and 1% presented with two endocrine symptoms. However, none of the patients had three endocrine manifestations. The level of one and two types of hormones was elevated in 52 (74.3%) and 5 (7.1%) patients, respectively and that of three types of hormones was increased only in one patient. Immunohistochemical staining for PRL + TSH or FSH/LH was most commonly performed (n = 17), followed by that for PRL + GH + ACTH and PRL + GH + TSH or FSH/LH (n = 14) and PRL + ACTH (n = 10). The primary culture results in vitro were consistent with the pathological findings in five (41.7%) patients. Moreover, 4 of 12 patients diagnosed with PPA during 2019-2020 tested positive for SOX2.

Conclusion: The pathogenesis of PPA remains elusive due to the lack of specific clinical symptoms and endocrine changes. Examination of hormones on tumor culture supernatant is helpful for its diagnosis.

Keywords: SOX2; cell culture; clinicopathological characteristics diagnosis; personalized therapy; plurihormonal pituitary adenoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Liu X, Jiao Y, Wang R. Interpretation and enlightenment of the 2017 edition of the World Health Organization's classification of pituitary tumors. Chin Med J. (2018) 98:641–2. 10.3760/cma.j.issn.0376-2491.2018.09.001 - DOI - PubMed
    1. Teng L, Lu D. Comparison of classification of pituitary tumors between WHO (2004 edition) and WHO (2000 edition). Chin J Diag Pathol. (2007) 14:7–9. 10.3969/j.issn.1007-8096.2007.03.001 - DOI
    1. Wei L, Yue Z, Wang S. Immunopathological study of plurihormonal pituitary adenomas. Chin J Neurosurg. (2008) 13:208. 10.l13798/j.issn.1009-153x.2008.04.025 - DOI
    1. Ho DM, Hsu CY, Ting LT, Chiang H. Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification. Histopathology. (2001) 39:310–9. 10.1046/j.1365-2559.2001.01204.x - DOI - PubMed
    1. Zhou F, Zhang M, Lei T. Analysis of clinical and pathological characteristics of GH-secreling pituitary adenomas and mixed pituitary adenomas in 120 patients. Chin J Clin Neurosurg. (2010) 15:92. 10.3969/j.issn.1009-153X.2010.02.009 - DOI